| CELLDEX THER. DL-,001 |
| USA |
| Gesundheit |
| US15117B2025 / A2PEAB |
| TCE2 (Frankfurt) / CLDX (NASDAQ) |
| FRA:TCE2, ETR:TCE2, TCE2:GR, NASDAQ:CLDX |
| - |
| https://www.celldex.com/ |
|
Celldex Therapeutics Inc. is a biopharmaceutical company focused on developing antibody-based therapies for severe inflammatory, allergic, and autoimmune diseases. The company’s current programs center on monoclonal and bispecific antibodies design..
>Volltext.. |
| 2614.63 Mio. EUR |
| 1996.58 Mio. EUR |
| 0.14 Mio. EUR |
| -280.74 Mio. EUR |
| -261.68 Mio. EUR |
| -3.8 EUR |
| 4.27 Mio. EUR |
| 41.32 Mio. EUR |
| -205.1 Mio. EUR |
| 11.6 |
| -97.19% |
| -55.31% |
| - |
| - |
| - |
| - |
| CELLDEX |
| 22.09.26 |
|